CN119173515A - 泛素特异性蛋白酶1 (usp1)的小分子抑制剂和其用途 - Google Patents
泛素特异性蛋白酶1 (usp1)的小分子抑制剂和其用途 Download PDFInfo
- Publication number
- CN119173515A CN119173515A CN202280087722.8A CN202280087722A CN119173515A CN 119173515 A CN119173515 A CN 119173515A CN 202280087722 A CN202280087722 A CN 202280087722A CN 119173515 A CN119173515 A CN 119173515A
- Authority
- CN
- China
- Prior art keywords
- optionally substituted
- alkyl
- heterocycloalkyl
- cycloalkyl
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/130284 | 2021-11-12 | ||
| CN2021130284 | 2021-11-12 | ||
| CN2022123821 | 2022-10-08 | ||
| CNPCT/CN2022/123821 | 2022-10-08 | ||
| PCT/CN2022/131290 WO2023083285A1 (en) | 2021-11-12 | 2022-11-11 | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119173515A true CN119173515A (zh) | 2024-12-20 |
Family
ID=86335132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280087722.8A Pending CN119173515A (zh) | 2021-11-12 | 2022-11-11 | 泛素特异性蛋白酶1 (usp1)的小分子抑制剂和其用途 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20250066348A1 (https=) |
| EP (1) | EP4430049A4 (https=) |
| JP (1) | JP2024543497A (https=) |
| KR (1) | KR20240117555A (https=) |
| CN (1) | CN119173515A (https=) |
| AU (1) | AU2022387669A1 (https=) |
| CA (1) | CA3235603A1 (https=) |
| CL (1) | CL2024001398A1 (https=) |
| CO (1) | CO2024006278A2 (https=) |
| CR (1) | CR20240190A (https=) |
| DO (1) | DOP2024000081A (https=) |
| GE (1) | GEAP202416531A (https=) |
| IL (1) | IL312640A (https=) |
| JO (1) | JOP20240095A1 (https=) |
| MX (1) | MX2024005756A (https=) |
| PE (1) | PE20241350A1 (https=) |
| WO (1) | WO2023083285A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312642A (en) | 2021-11-12 | 2024-07-01 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| WO2023155866A1 (zh) * | 2022-02-18 | 2023-08-24 | 四川海思科制药有限公司 | 一种吡唑并吡啶衍生物及其在医药上的应用 |
| WO2024022266A1 (en) * | 2022-07-25 | 2024-02-01 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heteroaryl compounds as inhibitors of usp1 |
| WO2024032647A1 (zh) * | 2022-08-09 | 2024-02-15 | 上海济煜医药科技有限公司 | 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途 |
| JP2025531133A (ja) * | 2022-09-20 | 2025-09-19 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | ユビキチン特異的プロテアーゼ阻害剤としてのカルボニル縮合複素環誘導体 |
| CN120603835A (zh) * | 2023-01-20 | 2025-09-05 | 杭州英创医药科技有限公司 | 作为usp1抑制剂的化合物 |
| KR20260033560A (ko) * | 2023-07-05 | 2026-03-10 | 장슈 야홍 메디텍 코퍼레이션 리미티드 | 피리미딘 화합물, 이의 제조 방법 및 이의 의학적 용도 |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| WO2025015905A1 (en) * | 2023-07-14 | 2025-01-23 | Laekna Therapeutics Shanghai Co., Ltd. | Pyrimidine compounds and their use as usp1 inhibitors |
| TW202530200A (zh) * | 2023-09-25 | 2025-08-01 | 大陸商上海濟煜醫藥科技有限公司 | 嗒𠯤酮類化合物作為泛素－特異性蛋白酶１抑制劑的製備方法、應用及其用途 |
| TW202530229A (zh) * | 2023-09-26 | 2025-08-01 | 大陸商上海濟煜醫藥科技有限公司 | 氮雜環胺類化合物作為泛素-特異性蛋白酶１抑制劑的製備方法、應用及其用途 |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| TW202539659A (zh) | 2024-01-10 | 2025-10-16 | 美商維瑞斯治療股份有限公司 | Ｄｎａ損傷修復途徑的新穎抑制劑 |
| WO2025227060A1 (en) * | 2024-04-26 | 2025-10-30 | Insilico Medicine Ip Limited | Heterocyclic inhibitors of ubiquitin specific protease 1 (usp1) in combination with additional agents for use in the treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108473495B (zh) * | 2015-11-20 | 2022-04-12 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
| US11485736B2 (en) * | 2018-12-20 | 2022-11-01 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
| WO2021163530A1 (en) * | 2020-02-14 | 2021-08-19 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
| KR20230098186A (ko) * | 2020-10-30 | 2023-07-03 | 케이에스큐 세러퓨틱스 인코포레이티드 | 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도 |
| EP4291559A1 (en) * | 2021-02-15 | 2023-12-20 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
| WO2022197892A1 (en) * | 2021-03-17 | 2022-09-22 | Tango Therapeutics, Inc. | Purine derivatives as anticancer agents |
| WO2022199652A1 (en) * | 2021-03-24 | 2022-09-29 | Impact Therapeutics (Shanghai) , Inc | Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof |
| CA3214040A1 (en) * | 2021-04-07 | 2022-10-13 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 1 (usp1) |
-
2022
- 2022-11-11 EP EP22892078.1A patent/EP4430049A4/en active Pending
- 2022-11-11 IL IL312640A patent/IL312640A/en unknown
- 2022-11-11 CA CA3235603A patent/CA3235603A1/en active Pending
- 2022-11-11 JP JP2024528586A patent/JP2024543497A/ja active Pending
- 2022-11-11 US US18/708,686 patent/US20250066348A1/en active Pending
- 2022-11-11 WO PCT/CN2022/131290 patent/WO2023083285A1/en not_active Ceased
- 2022-11-11 AU AU2022387669A patent/AU2022387669A1/en active Pending
- 2022-11-11 MX MX2024005756A patent/MX2024005756A/es unknown
- 2022-11-11 CN CN202280087722.8A patent/CN119173515A/zh active Pending
- 2022-11-11 GE GEAP202416531A patent/GEAP202416531A/en unknown
- 2022-11-11 CR CR20240190A patent/CR20240190A/es unknown
- 2022-11-11 PE PE2024001034A patent/PE20241350A1/es unknown
- 2022-11-11 KR KR1020247018880A patent/KR20240117555A/ko active Pending
-
2024
- 2024-04-24 JO JOJO/P/2024/0095A patent/JOP20240095A1/ar unknown
- 2024-05-09 CL CL2024001398A patent/CL2024001398A1/es unknown
- 2024-05-10 DO DO2024000081A patent/DOP2024000081A/es unknown
- 2024-05-17 CO CONC2024/0006278A patent/CO2024006278A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023083285A1 (en) | 2023-05-19 |
| CR20240190A (es) | 2024-09-13 |
| GEAP202416531A (en) | 2024-10-28 |
| DOP2024000081A (es) | 2024-11-29 |
| MX2024005756A (es) | 2024-09-06 |
| JP2024543497A (ja) | 2024-11-21 |
| PE20241350A1 (es) | 2024-07-03 |
| US20250066348A1 (en) | 2025-02-27 |
| JOP20240095A1 (ar) | 2024-04-24 |
| KR20240117555A (ko) | 2024-08-01 |
| IL312640A (en) | 2024-07-01 |
| EP4430049A4 (en) | 2025-12-17 |
| CL2024001398A1 (es) | 2024-11-08 |
| EP4430049A1 (en) | 2024-09-18 |
| AU2022387669A1 (en) | 2024-05-16 |
| CO2024006278A2 (es) | 2024-05-30 |
| CA3235603A1 (en) | 2023-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN119173515A (zh) | 泛素特异性蛋白酶1 (usp1)的小分子抑制剂和其用途 | |
| CN119173512A (zh) | 泛素特异性蛋白酶1 (usp1)的小分子抑制剂和其用途 | |
| JP7181967B2 (ja) | 一過性受容体電位ａ１イオンチャネルの阻害 | |
| CN119110804A (zh) | Kras调节剂及其用途 | |
| CN119604501A (zh) | 基于嘧啶的调节剂及其用途 | |
| CN119053601A (zh) | 泛素特异性蛋白酶1(usp1)的小分子抑制剂及其用途 | |
| WO2025049619A1 (en) | Kras modulators and uses thereof | |
| CN115335057A (zh) | 抑制酪蛋白激酶的方法 | |
| CN111072676B (zh) | 含氮稠合三环衍生物及其用途 | |
| OA21706A (en) | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof. | |
| CA3235762A1 (en) | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof | |
| CN110922408B (zh) | 3H-[1,2,3]三唑并[4,5-d]嘧啶-5-胺衍生物及其用途 | |
| OA21708A (en) | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof. | |
| EA050901B1 (ru) | Низкомолекулярные ингибиторы убиквитин-специфической протеазы 1 (usp1) и их применение | |
| OA21707A (en) | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof. | |
| HK1241285A1 (en) | Inhibiting the transient receptor potential a1 ion channel | |
| HK1241285B (en) | Inhibiting the transient receptor potential a1 ion channel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |